TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Brief Summary: The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B
C: Arm Label: KU-0059436 (AZD2281) 100 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Arm Label: KU-0059436 (AZD2281) 400 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 100 mg BID | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 400 mg BID
D: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Brief Summary: The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
B: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B
D: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: Varenicline + Patch Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline Only Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline + Patch Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch | Arm Label: Varenicline Only Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration | Intervention Type: OTHER; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: OTHER; Name: Placebo Pill; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Standard Duration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Electronic cigarettes; Type: EXPERIMENTAL; Interventions: Other: disposable electronic cigarettes | Intervention Type: OTHER; Name: disposable electronic cigarettes; Assigned to Arm(s): Electronic cigarettes
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
B: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Smoking reduction intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking reduction intervention | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and diet advice control | Intervention Type: BEHAVIORAL; Name: Smoking reduction intervention; Assigned to Arm(s): Smoking reduction intervention arm | Intervention Type: BEHAVIORAL; Name: Exercise and diet advice control; Assigned to Arm(s): Control arm
C: Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers
D: Arm Label: Gradual reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction Phone Counseling, Drug: Pre-Quit Nicotine Lozenges, Drug: Post-Quit Nicotine Lozenges | Arm Label: Abrupt cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Intervention Type: BEHAVIORAL; Name: Reduction Phone Counseling; Assigned to Arm(s): Gradual reduction | Intervention Type: BEHAVIORAL; Name: Abrupt Phone Counseling; Assigned to Arm(s): Abrupt cessation | Intervention Type: BEHAVIORAL; Name: Minimal Abrupt Phone Counseling; Assigned to Arm(s): Minimal intervention | Intervention Type: DRUG; Name: Pre-Quit Nicotine Lozenges; Assigned to Arm(s): Gradual reduction | Intervention Type: DRUG; Name: Post-Quit Nicotine Lozenges; Assigned to Arm(s): Abrupt cessation, Gradual reduction, Minimal intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Motivational Text Messages; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Text Messages | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Motivational Text Messages; Assigned to Arm(s): Motivational Text Messages | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill

Answer: C